A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin

作者：Delavenne Xavier^*; Ollier Edouard; Basset Thierry; Bertoletti Laurent; Accassat Sandrine; Garcin Arnauld; Laporte Silvy; Zufferey Paul; Mismetti Patrick

来源：British Journal of Clinical Pharmacology, 2013, 76(1): 107-113.

DOI：10.1111/bcp.12055

• bioavailability
• clarithromycin
• dabigatran
• drug-drug interaction
• P-glycoprotein inhibition
• population pharmacokinetics and pharmacodynamics

Aim The aim of this study was to develop a PK/PD model to assess drug-drug interactions between dabigatran and P-gp modulators, using the example of clarithromycin, a strong inhibitor of P-gp. Methods Ten healthy male volunteers were randomized to receive in the first treatment period a single 300mg dose of dabigatran etexilate (DE) and in the second treatment period 500mg clarithromycin twice daily during 3 days and then 300mg DE plus 500mg clarithromycin on the fourth day, or the same treatments in the reverse sequence. Dabigatran plasma concentration and ecarin clotting time (ECT) were measured on 11 blood samples. Models were built using a non-linear mixed effect modelling approach. Results The best PK model was based on an inverse Gaussian absorption process with two compartments. The relationship between dabigatran concentration and ECT was implemented as a linear function. No continuous covariate was associated with a significant decrease in the objective function. The concomitant administration of clarithromycin induced a significant change only in DE bioavailability, which increased from 6.5% to 10.1% in the presence of clarithromycin. Clarithromycin increased peak concentration and AUC by 60.2% and 49.1% respectively. Conclusion The model proposed effectively describes the complex PK of dabigatran and takes into account drug-drug interactions with P-gp activity modulators, such as clarithromycin.

• 出版日期2013-7